Focus Partners Wealth
GANX icon

Focus Partners Wealth’s Gain Therapeutics GANX Stock Holding History

Focus Partners Wealth’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,855
Closed -$251K – 2724
2025
Q4 		$251K Buy
+77,855
New +$208K ﹤0.01% 2322

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Focus Partners Wealth's GANX Position: Q1 2026 in Review

Focus Partners Wealth sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 77,855 shares — an estimated $251K sold.

Focus Partners Wealth first reported a position in GANX in Q4 2025 and held it in 1 quarter. The position peaked at $251K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Focus Partners Wealth reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 77,855 Gain Therapeutics shares in Q1 2026, an estimated $251K.
  • Focus Partners Wealth first reported a position in Gain Therapeutics in Q4 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Gain Therapeutics position peaked at $251K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.